Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease by Jiang, Z. Gordon & Tapper, Elliot B.
This is the author manuscript accepted for publication and has undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/HEP4.1386
This article is protected by copyright. All rights reserved
DR. ZHENGHUI GORDON JIANG (Orcid ID : 0000-0003-0495-9940)
DR. ELLIOT B. TAPPER (Orcid ID : 0000-0002-0839-1515)
Article type      : Invited: Editorial
Cost-saving or cost-effective? Unanswered Questions in the Screening of Patients with 
Nonalcoholic Fatty Liver Disease
Z. Gordon Jiang 1, Elliot B. Tapper 2
1 Division of Gastroenterology & Hepatology, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA
2 Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 
Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI,
Correspondence
Z. Gordon Jiang
Division of Gastroenterology and Hepatology
Beth Israel Deaconess Medical Center























The authors declare no conflict of interest relevant to this study. 
Nonalcoholic fatty liver disease (NAFLD) affects approximately one-third of the North 
American population, among whom up to 5% may develop cirrhosis.(1, 2) Within the spectrum 
of NAFLD’s histological features, the presence of advanced fibrosis best predicts long-term 
outcomes.(3) Increasing awareness of NAFLD has led to an inevitable question: should we 
screen for NAFLD; and if so, how should we do this?
To Screen, or Not To Screen? 
The newly updated guideline from the American Association for the Study of Liver 
Diseases (AASLD) recommended against routine screening for NAFLD among high-risk groups, 
including diabetes and obesity.(4) This recommendation is not based on evidence to support 
screening but rather the lack thereof. Yet the concept of screening remains attractive. Screening 
is useful when the disease is serious and has a detectable and reasonably prevalent pre-clinical 
phase. NASH cirrhosis is devastating and always preceded by fibrosis. Fibrosis, in turn, occurs 
in many but not all patients with NAFLD. It is unclear, however, whether there is a strategy that 
safely (with minimal false-negatives) and cost-effectively discerns a high-risk group.
Choosing a Screening Strategy
Cost is a barrier to screening. This includes both the cost of screening and cost from 
ineffective screening. Inexpensive tools to detect fibrosis developed in the past decade have 
made screening feasible.  These tools are often validated in selected cohorts and share similar 
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(LSM) provided by the point-of-care vibration-controlled transient elastography (VCTE) device 
are best studied.(5, 6)  Although VCTE provides better risk-discrimination overall, the free-to-
use FIB-4 algorithm has an intrinsic advantage for cost containment. Some VCTE results can be 
unreliable (particularly at high body mass index) or inaccurate (in the context of substantial 
hepatic inflammation or hepatic vascular congestion), while FIB-4 may be more prone to 
misclassification for both the young and very old. Each test yields a continuous value that can 
be dichotomized to maximize negative and positive predictive values. For this reason, some 
investigators advocate for a staged approach the combines stringent FIB-4 cutoffs to eliminate 
low-risk persons followed by VCTE (or other tests) to discern those at high-risk.(7) This staged 
strategy is expected to reduce the cost of fibrosis screening significantly. Real-world data are 
limited to confirm the safety and utility of this approach. 
Study Findings
Addressing this gap, Davyduke and colleagues leveraged a NAFLD referral program 
within the catchment of the University of Alberta to compare a two-stage approach with the 
existing single-step VCTE-based strategy. Specifically, they evaluated 560 patients between 16-
65 years of age with elevated ALT or steatosis on imaging who underwent VCTE upon referral. 
Using a threshold LSM of ≥8.0 kPa for advanced fibrosis, the authors described the impact of a 
‘FIB-4 first’ strategy to reduce the need for VCTE and Hepatology referral. Decision modeling 
identified a FIB-4 value of 1.3 as in inflection point after which the post-test probability of high 
LSM exceeded 12.5%. Implementing this strategy would have obviated the need for 489 (87%) 
VCTE examinations and prevented 50 (69%) hepatology referrals. However, this strategy would 
also have missed >41 (68%) at-risk patients with high LSM. Indeed 53 of 489 subjects with FIB-
4<1.3 had high or invalid LSM, 29 of whom were evaluated further and 3 had F3-F4 fibrosis on 
biopsy. These findings were robust across age and body mass indices.
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A heightened awareness of NAFLD has led to innovative strategies to identify at-risk 
patients across the globe. These programs are made possible by the use of noninvasive 
modalities for fibrosis risk-assessment and involve a concerted effort by primary care and 
hepatology communities. Davyduke et al. shed light on both the cost-savings as well as 
potential pitfalls of a FIB-4 first staged strategy in comparison to the one-step VCTE approach 
that was in place at the time of the study. Additional data are needed to clarify the risks and 
benefits of this approach.
This is Progress, but Caution is Advised
At least four concepts must be considered to contextualize these data. First, our reach 
may exceed our grasp. It is unknown how many patients were misclassified by the noninvasive 
strategy. In the post-biopsy era, outcomes alone can be used to calibrate test cut-offs and 
balance the risks and benefits of screening. This demands controlled studies paired with 
longitudinal follow-up. Second, patients in this study were referred. The prevalence of at-risk 
individuals may not mirror those in the community, and this will impact test performance. Third, 
the conclusions of this study presuppose the availability of resources (e.g., VCTE) that may be 
lacking in many settings. Fourth, the generalizability of this program assumed uniform risk-
tolerance and practices concerning confirmatory measurements for fibrosis risk. Indeed, this 
strategy will miss patients with advanced fibrosis, and the cost-savings require that patients and 
clinicians accept the results of VCTE with limited need for biopsy. This is precisely why 
prospective studies that account for downstream clinical processes are needed. Yet, regardless 
of the strategy design, it seems certain that a proactive screening is superior to the passive 
waiting of fibrosis progression. Those primary care providers and hepatologists exploring 
innovative strategies are on the right track. 
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